Table 3 Emerging interventions and drugs used in PC clinical trials or in PC preclinical models targeting Trk A, B, C receptors or activity
Type | Interventions | Study name | Condition/disease | Development stage | Refs or Study number |
|---|---|---|---|---|---|
Pan Trk inhibitor and RTKs | CEP-701 (lestaurtinib) | Study of CEP-701 in Treatment of PC | PC | Phase 2 | NCT00081601 |
TrkA,TrkB, TrkC, ROS1, ALK inhibitor | Entrectinib (RXDX-101) | STARTRK-1 | PC and locally advanced or metastatic cancer confirmed to be positive for NTRK1, NTRK2, NTRK3, ROS1, or ALK molecular alterations | Phase 1 | NCT02097810 |
Trk A selective inhibitor | VMD-928 | Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma | PC and advanced solid tumors or lymphoma | Phase I | NCT03556228 |
Pan-Trk kinase activity inhibitor | TQB3811 | Phase I Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors | advanced malignant solid tumor | Phase I | NCT05046847 |
Pan-TRK inhibitor | NOV1601(CHC2014) | A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies | solid organ malignancies | Phase I | NCT04014257 |
ALK and pan-Trk inhibitor | TSR-011 | A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors | solid tumors | Phase I | NCT02048488 |
ROS1 and pan-Trk inhinitor | DS-6051b | A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b | solid tumors | Phase I | NCT02279433 |
Pan-Trk inhibitor | ONO-7579 | ONTRK | solid tumors | Phase I | NCT03182257 |
Trk A inhibitor | GW441756 | CRPC derived cells | Preclinical studies | [76] | |
Trk A constitutive Phosphorylation inhibitor | Altiratinib | PC-3 cells | Preclinical studies | [89] |